![]() |
市場調查報告書
商品編碼
2081871
內視鏡設備市場:2026-2032年全球市場預測(產品類型、檢驗目的、易用性、系統配置、臨床適應症、最終用戶及患者年齡層分類)Endoscopy Equipment Market by Product Category, Procedure Intent, Usability, System Configuration, Clinical Indication, End User, Patient Age Group - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,內視鏡設備市場將成長至 601.6 億美元,複合年成長率為 7.65%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 359億美元 |
| 預計年份:2026年 | 384億美元 |
| 預測年份 2032 | 601.6億美元 |
| 複合年成長率 (%) | 7.65% |
內視鏡設備在胃腸病學、呼吸內科、泌尿系統、婦科、耳鼻喉科和外科等領域的微創診斷和治療中發揮核心作用。癌症、胃腸道疾病、肥胖相關疾病和老齡化相關慢性疾病的日益嚴重,推動了對內視鏡設備的需求。聯合國預測,到2050年,全球65歲以上人口將增加一倍以上。
內視鏡設備市場格局正因癌症篩檢提前、門診治療模式轉變、感染控制要求日益嚴格以及從診斷性內視鏡檢查向先進內視鏡治療的轉型而發生重塑。美國預防服務工作小組(USPSTF)建議45至75歲族群進行大腸癌篩檢,推動了成熟市場對相關檢查的持續需求,並提高了人們對高通量內視鏡實驗室的興趣。
人工智慧 (AI) 正在成為內視鏡檢查(尤其是大腸鏡檢查)中電腦輔助偵測 (CAD) 的一項可衡量的效能提升手段。 2021 年,FDA 批准了 GI Genius,這是首款基於人工智慧的醫療設備,可幫助臨床醫生即時檢測結直腸病變,從而為人工智慧輔助內視鏡工作流程建立了監管途徑。
亞太地區是主要的成長引擎,這得益於龐大的病患群體、不斷擴充的醫院基礎設施以及對癌症篩檢和微創醫療投入的增加。特別是中國、印度、日本、韓國和澳大利亞,其公共和私人醫療保健系統的需求差異化成長。北美地區仍然是一個高價值地區,這得益於完善的醫保報銷機制、較高的結直腸癌篩檢率、門診手術能力以及人工智慧驅動的高解析度一次性內視鏡技術的快速普及。
隨著印尼、泰國、越南、馬來西亞、菲律賓和新加坡等國獲得專業醫療服務的機會增加、私人內視鏡技術水平提高以及醫院現代化投資的推進,東協市場正在擴張。海灣合作理事會(GCC)國家在高階醫院基礎設施建設、數位化手術室引進和胃腸專科服務拓展方面也取得了進展。同時,歐盟在醫療設備法規協調、公共篩選項目以及強調安全性、文件記錄和全生命週期性能的嚴格採購標準方面取得了成功。
美國在檢查數量、人工智慧商業化、門診內視鏡中心的建立以及結直腸癌篩檢活動方面主導,而加拿大則專注於品管的公共服務、省級篩檢計畫和標準化臨床路徑。在墨西哥和巴西,私人醫院網路和專科胃腸病服務的擴張催生了對耐用、易於維護的內視鏡設備、靈活的資金籌措和可靠的再處理解決方案的需求。
業內供應商應優先考慮基於實證醫學的產品差異化,例如增強腺瘤檢測能力、降低交叉感染風險、符合人體工學的設計、提高產品周轉率以及與內視鏡報告系統的無縫整合。供應商必須根據高階醫院的需求和注重成本的新興市場的需求調整產品系列,同時確保與當地的基礎設施、服務能力和臨床培訓水平相容。
本執行摘要基於二手研究,參考了權威的公共資訊來源,包括監管機構、公共衛生機構、臨床指南制定組織、同行評審文獻和行業資訊披露。主要參考資料包括世界衛生組織和全球癌症研究聯盟(GLOBOCAN)的癌症統計數據、聯合國人口統計數據、美國預防服務工作組(USPSTF)的篩檢建議、美國食品藥物管理局(FDA)的醫療設備認證和安全資訊、歐盟醫療器材法規(MDR)的要求以及經認證的內視鏡學會的指南。
隨著早期診斷、微創治療、感染預防和手術效率在醫療保健系統中日益受到重視,內視鏡設備市場預計將保持其重要性。人口老化、癌症篩檢需求、慢性胃腸道疾病以及向門診和數位化醫療的轉變是推動市場需求的主要因素。
The Endoscopy Equipment Market is projected to grow by USD 60.16 billion at a CAGR of 7.65% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 35.90 billion |
| Estimated Year [2026] | USD 38.40 billion |
| Forecast Year [2032] | USD 60.16 billion |
| CAGR (%) | 7.65% |
Endoscopy equipment is central to minimally invasive diagnosis and therapy across gastroenterology, pulmonology, urology, gynecology, ENT, and surgical specialties. Demand is supported by the documented burden of cancer, gastrointestinal disease, obesity-related disorders, and age-associated chronic conditions, with the United Nations projecting the global population aged 65 and older to more than double by 2050.
The industry is moving beyond conventional scopes toward high-definition visualization, single-use endoscopes, capsule endoscopy, endoscopic ultrasound, therapeutic accessories, automated reprocessing systems, and AI-assisted detection. For healthcare providers, the strategic priority is clear: improve diagnostic yield, reduce procedure-related risk, and expand procedure capacity without compromising infection prevention or regulatory compliance.
The endoscopy equipment landscape is being reshaped by earlier cancer screening, outpatient migration, stricter infection-control expectations, and the shift from diagnostic procedures to advanced endoscopic therapy. The U.S. Preventive Services Task Force recommends colorectal cancer screening from age 45 to 75, reinforcing sustained procedural demand in mature markets and increasing interest in high-throughput endoscopy suites.
Technology adoption is also changing purchasing behavior. Hospitals and ambulatory surgery centers are prioritizing 4K and 3D visualization, narrow-band and image-enhanced imaging, disposable components, ergonomic scope design, and connected platforms that support documentation, quality metrics, and lifecycle service models. These shifts are increasing the importance of interoperability, cybersecurity, validated cleaning protocols, and staff training in endoscopy system selection.
Artificial intelligence is becoming a measurable performance enhancer in endoscopy, particularly in computer-aided detection for colonoscopy. The FDA authorized GI Genius in 2021 as the first AI-based device to assist clinicians in detecting colon lesions in real time, validating a regulated pathway for AI-assisted endoscopic workflows.
The cumulative impact of AI extends beyond lesion detection. AI can support procedure documentation, image triage, quality benchmarking, withdrawal-time analytics, training feedback, and operational scheduling. However, clinical adoption depends on validated datasets, workflow integration, cybersecurity, explainability, and physician oversight, as AI tools augment rather than replace clinical judgment.
Asia-Pacific is a major growth engine due to large patient populations, expanding hospital infrastructure, and rising investments in cancer screening and minimally invasive care, with China, India, Japan, South Korea, and Australia driving differentiated demand across public and private healthcare systems. North America remains a high-value region, supported by reimbursement structures, strong colorectal cancer screening adherence, ambulatory procedure capacity, and rapid adoption of AI-enabled, high-definition, and single-use endoscopy technologies.
Europe benefits from organized screening programs, established clinical guidelines, and strong medical device quality standards under the EU MDR framework, while Latin America is advancing through private hospital expansion and broader access to gastrointestinal and surgical endoscopy in countries such as Brazil and Mexico. The Middle East is investing in specialist hospitals, digital health infrastructure, and medical tourism, particularly in GCC countries, while Africa shows long-term opportunity as diagnostic capacity, workforce training, maintenance capability, and reprocessing infrastructure improve.
ASEAN markets are expanding as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore increase specialty-care access, private-sector endoscopy capacity, and investment in hospital modernization. The GCC is advancing premium hospital infrastructure, digital operating room adoption, and specialized digestive disease services, while the European Union benefits from harmonized medical device regulation, public screening programs, and strong procurement standards that emphasize safety, documentation, and lifecycle performance.
BRICS economies represent scale-led opportunity, with China, India, and Brazil expanding procedure access and Russia and South Africa sustaining demand through tertiary-care networks and public-sector modernization. G7 countries lead in clinical guideline adoption, AI validation, premium imaging platforms, and quality-measure reporting. NATO countries add relevance through healthcare resilience, cybersecurity expectations, supply chain continuity, and standardized procurement practices across many high-income health systems.
The United States leads in procedure volume, AI commercialization, ambulatory endoscopy center adoption, and colorectal cancer screening activity, while Canada emphasizes quality-controlled public access, provincial screening programs, and standardized clinical pathways. Mexico and Brazil are expanding private hospital networks and specialty gastroenterology services, creating demand for durable, serviceable endoscopy equipment, flexible financing, and reliable reprocessing solutions.
In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established screening policies, aging populations, advanced hospital procurement, and strong clinical governance, while Russia relies on regional modernization and tertiary-care demand. China and India are scaling access rapidly through hospital expansion and rising specialist capacity, Japan and South Korea lead in advanced visualization, early cancer detection, and high procedural standards, and Australia combines strong screening participation, regulatory oversight, and demand for efficient endoscopy workflows.
Industry vendors should prioritize evidence-based product differentiation, including improved adenoma detection support, reduced cross-contamination risk, ergonomic design, faster turnover, and seamless integration with endoscopy reporting systems. Vendors should align product portfolios with both premium hospital requirements and cost-sensitive emerging-market needs, while ensuring compatibility with local infrastructure, service capabilities, and clinical training levels.
Strategic actions include investing in AI validation studies, building local service networks, offering flexible procurement models, training clinical users, and supporting regulatory readiness under FDA, EU MDR, and country-specific medical device rules. Providers should evaluate total cost of ownership, reprocessing capacity, cybersecurity, interoperability, uptime support, and staff training before platform selection.
This executive summary is based on secondary research from authoritative public sources, including regulatory agencies, public health organizations, clinical guideline bodies, peer-reviewed literature, and industry disclosures. Key reference points include WHO and GLOBOCAN cancer statistics, United Nations demographic data, USPSTF screening recommendations, FDA medical device authorizations and safety communications, EU MDR requirements, and recognized endoscopy society guidance.
The analysis triangulates disease burden, demographic trends, technology adoption, regional healthcare investment, reimbursement environment, regulatory developments, infection-control expectations, and clinical workflow requirements. Insights are structured to support endoscopy equipment, endoscopes, endoscopy systems, AI-assisted endoscopy, infection prevention, and minimally invasive diagnostic and therapeutic procedures.
The endoscopy equipment market is positioned for sustained relevance as healthcare systems prioritize earlier diagnosis, minimally invasive therapy, infection prevention, and procedure efficiency. Demand is supported by aging populations, cancer screening needs, chronic gastrointestinal disease, and the shift toward outpatient and digitally enabled care.
Competitive advantage will increasingly depend on clinically validated innovation, robust service coverage, regulatory compliance, infection-control performance, and AI-enabled workflow value. Organizations that combine advanced visualization, responsible AI, scalable training, and lifecycle support will be best placed to strengthen clinical impact and long-term adoption.